ABT logo
Abbott Laboratories(ABT)
Last print unknown agoAbout this dataData status
$104.06▼-0.83 (-0.79%)Stale · unknown oldEarnings tomorrow

ABT R&D Expenses

$3.16BTTM · USD

Period ending:

ABT FY R&D ExpensesUSD
ABT FY R&D Expenses1985-12-31: $0.001986-12-31: $0.001987-12-31: $0.001988-12-31: $0.001989-12-31: $0.001990-12-31: $0.001991-12-31: $0.001992-12-31: $0.001993-12-31: $880.97M1994-12-31: $963.52M1995-12-31: $1.07B1996-12-31: $1.20B1997-12-31: $1.30B1998-12-31: $1.22B1999-12-31: $1.19B2000-12-31: $1.35B2001-12-31: $1.58B2002-12-31: $1.56B2003-12-31: $1.73B2004-12-31: $1.70B2005-12-31: $1.81B2006-12-31: $2.23B2007-12-31: $2.40B2008-12-31: $2.69B2009-12-31: $2.74B2010-12-31: $3.57B2011-12-31: $4.06B2012-12-31: $1.54B2013-12-31: $1.37B2014-12-31: $1.29B2015-12-31: $1.37B2016-12-31: $1.36B2017-12-31: $2.13B2018-12-31: $2.29B2019-12-31: $2.41B2020-12-31: $2.42B2021-12-31: $2.74B2022-12-31: $2.85B2023-12-31: $2.72B2024-12-31: $2.82B2025-12-31: $2.96B$4.06B$0.00
1985-12-312025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in USD. Dates are period ends; a fiscal year may differ from a calendar year.

ABT r&d expenses history

Research and development spending. The available annual fiscal periods series contains 41 observations from Dec 31, 1985 to Dec 31, 2025.

Abbott Laboratories R&D Expenses — Annual fiscal periods (USD)
Period endingR&D Expenses (USD)
2,955,000,000
2,823,000,000
2,719,000,000
2,852,000,000
2,738,000,000
2,418,000,000
2,408,000,000
2,288,000,000
2,130,000,000
1,358,000,000
1,369,000,000
1,286,000,000
1,371,000,000
1,544,000,000
4,060,414,000
3,572,424,000
2,743,733,000
2,688,811,000
2,402,649,000
2,226,271,000
1,811,175,000
1,696,753,000
1,733,472,000
1,561,792,000
1,577,552,000
1,351,024,000
1,193,963,000
1,221,593,000
1,302,403,000
1,204,841,000
1,072,745,000
963,516,000
880,974,000
0
0
0
0
0
0
0
0

Compare r&d expenses

All ABT financial metrics · ABT stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.